NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
Clinical Trials
652 trialsNCT06257264 2026-04-22
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07545811 2026-04-22
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics
Phase 1 Recruiting
NCT07543055 2026-04-21
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Regeneron Pharmaceuticals
Phase 1 Not yet recruiting
NCT05800665 2026-04-20
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Genentech, Inc.
Phase 1 Recruiting
NCT05997615 2026-04-20
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT06465069 2026-04-20
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT07219147 2026-04-20
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT05022849 2026-04-17
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Janssen Research & Development, LLC
Phase 1 Completed
NCT06545942 2026-04-17
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Active not recruiting
NCT07114601 2026-04-17
OMNIRAY
Eli Lilly and Company
Phase 1 Recruiting
NCT07236112 2026-04-15
Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer
C Ray Therapeutics
Phase 1 Active not recruiting
NCT01480154 2026-04-13
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02123758 2026-04-13
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT03523442 2026-04-13
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04577833 2026-04-13
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04644770 2026-04-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04662580 2026-04-13
ARX517
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04898634 2026-04-13
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06238479 2026-04-13
EXCEED
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06582017 2026-04-13
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Phase 1 Recruiting
NCT06982222 2026-04-13
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07082920 2026-04-13
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07319871 2026-04-13
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06801236 2026-04-09
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Acerand Therapeutics Limited
Phase 1 Recruiting
NCT06303713 2026-04-08
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT07517198 2026-04-08
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
Phase 1 Recruiting
NCT05079698 2026-04-07
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT07214961 2026-04-07
ARTISAN
ARTBIO Inc.
Phase 1 Active not recruiting
NCT07424547 2026-04-07
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Recruiting
NCT04147806 2026-04-03
PROSINT
Albert Einstein College of Medicine
Phase 1 Active not recruiting
NCT04931823 2026-04-03
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Terminated
NCT06451497 2026-04-02
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Phase 1 Recruiting
NCT07174063 2026-04-02
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer
Novartis
Phase 1 Recruiting
NCT07054346 2026-04-01
LUTACT
University of California, San Francisco
Phase 1 Recruiting
NCT03674814 2026-03-31
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
University of Chicago
Phase 1 Completed
NCT04886986 2026-03-31
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1 Active not recruiting
NCT03860272 2026-03-30
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Phase 1 Active not recruiting
NCT04221542 2026-03-30
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
Phase 1 Recruiting
NCT05398302 2026-03-30
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT04167969 2026-03-27
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07495293 2026-03-27
Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer
Yonsei University
Phase 1 Not yet recruiting
NCT07493512 2026-03-25
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 1 Not yet recruiting
NCT04514484 2026-03-23
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07103018 2026-03-23
STRIKE-001
K36 Therapeutics, Inc.
Phase 1 Recruiting
NCT07145177 2026-03-23
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT05283330 2026-03-20
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Phase 1 Recruiting
NCT06705686 2026-03-20
PHAROS
TechnoGenesys, Inc.
Phase 1 Recruiting
NCT06136598 2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05245006 2026-03-17
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
University of California, San Francisco
Phase 1 Active not recruiting